百草枯解毒方联合持续血液灌流治疗急性百草枯中毒的疗效及Presepsin的临床价值
该前瞻性随机对照试验纳入2013年7月至2017年6月河北医科大学附属哈励逊国际和平医院急诊科收治的152例中度急性百草枯中毒患者,随机分为血液灌流组(A组,n=35)、百草枯解毒方联合血液灌流组(B组,n=50)和百草枯解毒方联合持续血液灌流组(C组,n=67)。C组总有效率70.1%(47/67)显著高于A组34.3%(12/35)和B组54.0%(27/50),28天死亡率29.8%(20/67)显著低于A组65.7%(23/35)和B组46.0%(23/50)(均P<0.05)。血清Presepsin水平与百草枯含量及28天死亡率正相关(r1=0.917,r2=0.864,均P=0.001),Presepsin预测28天死亡的AUC为0.863,截断值1.22 μg/L时敏感度83.3%、特异度81.4%。
要点
- 中度APP患者中,百草枯解毒方联合持续血液灌流组28天死亡率29.8%(20/67),显著低于单纯血液灌流组65.7%(23/35)和联合间断血液灌流组46.0%(23/50)(均P<0.05)。
- 联合持续血液灌流组总有效率70.1%(47/67),显著高于单纯血液灌流组34.3%(12/35)和联合间断血液灌流组54.0%(27/50)。
- 血清Presepsin在治疗12小时达峰值(A组4.28±0.20 μg/L、B组3.87±0.25 μg/L、C组3.53±0.23 μg/L),随后逐渐下降,C组最低。
- 血清Presepsin与百草枯含量及28天死亡率正相关(r1=0.917,r2=0.864,均P=0.001)。
- Presepsin预测28天死亡AUC为0.863,截断值1.22 μg/L时敏感度83.3%、特异度81.4%、阳性预测值77.46%、阴性预测值86.42%。
适用人群与场景
- 河北医科大学附属哈励逊国际和平医院急诊科2013年7月至2017年6月收治的中度急性百草枯中毒患者152例。
诊断标准与关键阈值
- 血清Presepsin预测28天死亡的截断值为1.22 μg/L(AUC 0.863,敏感度83.3%,特异度81.4%)。
处置流程与药物剂量
- A组(n=35):仅接受2小时血液灌流3次,每次间隔8小时。
- B组(n=50):在血液灌流基础上接受百草枯解毒方1号(每2小时1次,直至粪便中检测不到百草枯成分)和2号(每日3次,共14天)。
- C组(n=67):接受百草枯解毒方联合持续血液灌流,直至血清中检测不到百草枯成分。
研究设计与关键结果
- 前瞻性随机对照试验,纳入152例中度急性百草枯中毒患者,随机分为A组(n=35)、B组(n=50)、C组(n=67)。
- C组总有效率70.1%(47/67)显著高于A组34.3%(12/35)和B组54.0%(27/50);C组28天死亡率29.8%(20/67)显著低于A组65.7%(23/35)和B组46.0%(23/50)(均P<0.05)。
- 治疗前3组丙氨酸氨基转移酶、肌酸激酶MB同工酶、血清肌酐、C反应蛋白、肿瘤坏死因子-α、白细胞介素-6和-10无显著差异;治疗后5天3组上述指标均较治疗前升高,C组升高程度最低;治疗后7天上述指标下降,C组尤为明显。
- 治疗前3组血清Presepsin和百草枯水平无显著差异;随治疗时间延长,A、B、C组Presepsin水平升高,12小时达峰值(μg/L:A组4.28±0.20、B组3.87±0.25、C组3.53±0.23),随后逐渐下降;百草枯含量自8小时起低于治疗前(mg/L:A组1.76±0.12 vs 2.12±0.17,B组1.57±0.08 vs 2.24±0.16,C组1.25±0.10 vs 2.14±0.18),呈时间依赖模式,C组最明显(均P<0.05)。
- 血清Presepsin水平与百草枯含量及28天死亡率正相关(r1=0.917,r2=0.864,均P=0.001)。
- Presepsin预测28天死亡AUC为0.863,截断值1.22 μg/L时敏感度83.3%、特异度81.4%、阳性预测值77.46%、阴性预测值86.42%。
证据类型、等级与局限
- 证据类型:前瞻性随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,早期给予百草枯解毒方联合持续血液灌流治疗可有效降低中度急性百草枯中毒患者Presepsin水平、降低死亡率、改善预后。
- 作者认为,Presepsin可评估急性百草枯中毒患者的预后。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the clinical effect of paraquat (PQ) detoxification recipe combined with continuous hemoperfusion (HP) in the treatment of patients with acute paraquat poisoning (APP) and clinical significance of soluble CD14 subtype (sCD14-st, Presepsin).
METHODS: A prospective randomized controlled trial was conducted. 152 patients with moderate APP admitted to Department of Emergency Medicine of Harrison International Peace Hospital Affiliated to Hebei Medical University from July 2013 to June 2017 were enrolled, and they were randomly divided into three groups. The patients in HP group (group A, n = 35) only received 2-hour HP for 3 times, 8 hours each time, those in PQ detoxification recipe combined with HP group (group B, n = 50) received PQ detoxification recipe 1 (once per 2 hours until no PQ component was found in faeces) and 2 (3 times a day for 14 days) beside HP. The others in PQ detoxification recipe combined with persistent HP group (group C, n = 67) received continuous HP until the PQ component in serum was not detected. The parameters of organ function and inflammatory factor, and blood Presepsin and PQ contents were determined before and after treatment. The curative effect and 28-day mortality were recorded. The correlations between serum Presepsin level and PQ content as well as 28-day mortality were analyzed with Pearson correlation analysis. Receiver operating characteristic curve (ROC) was plotted to analyze the predictive value of Presepsin on prognosis.
RESULTS: The total effective rate of group C was significantly higher than that of groups A and B [70.1% (47/67) vs. 34.3% (12/35), 54.0% (27/50)], and 28-day mortality was significantly lowered [29.8% (20/67) vs. 65.7% (23/35), 46.0% (23/50), both P < 0.05]. There was no significant difference in alanine aminotransferase (ALT), MB isoenzyme of creatine kinase (CK-MB), serum creatinine (SCr), C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukins (IL-6 and IL-10) before treatment among the three groups. Five days after treatment, the above parameters in the three groups were increased as compared with those before treatment, but the increase degree in group C was the lowest. At 7 days after treatment, the parameters were decreased, especially in group C. There was no significant difference in serum Presepsin and PQ levels before treatment among the three groups. With the prolongation of treatment time, the Prespsin levels in groups A, B, and C were increased, and peaked at 12 hours (μg/L: 4.28±0.20, 3.87±0.25, 3.53±0.23), then gradually decreased,and the PQ contents were lower than those before treatment from 8 hours (mg/L: 1.76±0.12 vs. 2.12±0.17, 1.57±0.08 vs. 2.24±0.16, 1.25±0.10 vs. 2.14±0.18), with a time dependence pattern, especially in group C (all P < 0.05) . Correlation analysis showed that blood Presepsin level was positively correlated with PQ content and 28-day mortality (r1 = 0.917, r2 = 0.864, both P = 0.001), suggesting that the higher the PQ content was, the higher the Presepsin level, and the higher the 28-day mortality was. ROC curve analysis showed that the area under ROC curve (AUC) of Presepsin predicting 28-day mortality was 0.863; when the cut-off value was 1.22 μg/L, the sensitivity was 83.3%, the specificity was 81.4%, the positive predictive value was 77.46%, and the negative predictive value was 86.42%.
CONCLUSIONS: Early administration of PQ detoxification recipe combined with continuous HP treatment can effectively reduce Presepsin level, decrease the mortality of patients with moderate APP, improve the prognosis. Presepsin can assess the prognosis of patients with APP.
参考来源
- Wang W, Li J, Zhu B, et al. [Curative effect of paraquat detoxification recipe combined with continuous hemoperfusion in the treatment of patients with APP and clinical value of Presepsin]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 29151409. doi:10.3760/cma.j.issn.2095-4352.2017.11.002
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。